M uch of our training in imaging has historically focused on the detection and diagnosis of disease. We have strived for over one-half a century for greater sensitivity and accuracy. Unfortunately, despite our best intentions, this focus on accuracy has far too often led us on a path toward overdiagnosis of disease rather than enabling meaningful improvements in risk stratification and therapeutic decision making (1,2). Fryback On the other hand, men were more likely to have a positive CCTA (odds ratio: 1.79; 95% CI: 1.45 to 3.04) than a positive stress test (stress electrocardiography and echo but not technetium Tc 99m sestamibi).
M uch of our training in imaging has historically focused on the detection and diagnosis of disease. We have strived for over one-half a century for greater sensitivity and accuracy. Unfortunately, despite our best intentions, this focus on accuracy has far too often led us on a path toward overdiagnosis of disease rather than enabling meaningful improvements in risk stratification and therapeutic decision making (1,2). Fryback and Thornbury (3) in their seminal paper highlighted the importance of thinking beyond disease detection and accuracy and reminded us to not test for the sake of testing but rather to help stratify risk and guide decision making that can afford improved clinical outcomes.
Over the last decade coronary computed tomography angiography (CCTA) has been validated as the noninvasive gold standard for the detection and exclusion of anatomical coronary artery disease, with several multicenter diagnostic accuracy studies particularly demonstrating high negative predictive value (4-6). CCTA has also been shown to provide robust prognostic information across a whole host of populations independent of traditional clinical risk assessment as well as help guide medical and interventional therapeutic decision making that can improve clinical outcomes in observational registries (7) (8) (9) (10) . Importantly, these findings have been shown in both women and men. However, while these data Tendyne Holdings, and Neovasc. Dr. Naoum has reported that he has no relationships relevant to the contents of this paper to disclose. REPRINT REQUESTS AND CORRESPONDENCE: Dr. Jonathon Leipsic, Centre for Heart Valve Innovation,
